Cancer vaccination trial with novel multiple peptides in previously treated advanced non-small cell lung cancer.

e13029 Background: Cell division cycle associated gene 1 (CDCA1) and insulin-like growth factor-II mRNA binding protein 3 (IMP-3) are novel cancer-testis antigen overexpressed in non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the safety, efficacy, and immunological response of a novel peptide vaccination therapy, CDCA1 and IMP-3, in patients with previously treated advanced NSCLC. Methods: Human histocompatibility leukocyte (HLA)-A2402 positive advanced NSCLC patients who failed to standard therapy were enrolled if they had a performance status of 3 or less, were 80 years or younger, and had adequate organ function. The cocktail of 2 peptides was subcutaneously injected with 1 mL of incomplete Freund’s adjuvant to axillary or inguinal regions weekly. Immunological response was evaluated with enzyme-linked immunospot assay before and after vaccinations every 4 weeks. Results: From November 2009 through December 2011, 20 patients (13 men and 7 women; median age, 65 years; range, 3...